ArticleBlood cancer journal2022
Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy.
Ghulam Rehman Mohyuddin, Rajshekhar Chakraborty, Gregory S Calip, Mustafa S Ascha, Xiaoliang Wang, Samuel M Rubinstein, Sascha Tuchman, Luciano Costa, Benjamin Haaland, Smith Giri and 3 more
Abstract readLetter
In one paragraphArticle in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Ghulam Rehman MohyuddinDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. g.mohyuddin@hci.utah.edu.ORCID 0000-0001-6464-783X Rajshekhar ChakrabortyDepartment of Hematology, Columbia University, New York, NY, USA.
Mustafa S AschaFlatiron Health, New York, NY, USA.
Xiaoliang WangFlatiron Health, New York, NY, USA.
Samuel M RubinsteinDepartment of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sascha TuchmanDepartment of Medicine, Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-2109-1573 Luciano CostaDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.ORCID 0000-0001-5362-2469 Benjamin HaalandDepartment of Population Sciences, University of Utah, Salt Lake City, UT, USA.
Smith GiriDivision of Hematology and Oncology, University of Alabama at Birmingham, Birmingham, AL, USA.
Douglas SborovDivision of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-4268-2698 Funding
Institutional Career DevelopmentKL2TR002002 · NCATS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PHILLIPS, SHANE A · 2016 to 2024
$6.8MNCATS NIH HHS KL2 TR002002
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Multiple MyelomaNeoplasms, Plasma CellADP-ribosyl Cyclase 1Antineoplastic Combined Chemotherapy ProtocolsHumansPrognosisADP-ribosyl Cyclase 1
Identifiers
PMID36526617
PMCPMC9758218
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390